Share This Page
Investigational Drug Information for Dihydrexidine
✉ Email this page to a colleague
What is the drug development status for Dihydrexidine?
Dihydrexidine is an investigational drug.
There have been 3 clinical trials for Dihydrexidine.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2013.
The most common disease conditions in clinical trials are Schizotypal Personality Disorder, Personality Disorders, and Disease. The leading clinical trial sponsors are New York State Psychiatric Institute, Larry J. Siever, and National Institute of Mental Health (NIMH).
Summary for Dihydrexidine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 231 |
| WIPO Patent Applications | 73 |
| Japanese Patent Applications | 37 |
| Clinical Trial Progress | Phase 2 (2013-04-01) |
| Vendors | 0 |
Recent Clinical Trials for Dihydrexidine
| Title | Sponsor | Phase |
|---|---|---|
| A D1 Agonist For Working Memory | National Institute of Mental Health (NIMH) | Phase 2 |
| A D1 Agonist For Working Memory | New York State Psychiatric Institute | Phase 2 |
| A D1 Agonist For Working Memory | Antonia New | Phase 2 |
Clinical Trial Summary for Dihydrexidine
Top disease conditions for Dihydrexidine
Top clinical trial sponsors for Dihydrexidine
US Patents for Dihydrexidine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Dihydrexidine Development Update, Patent Position, and Market Projection
Dihydrexidine is an investigational, selective dopamine D1/D5 receptor agonist that has not obtained FDA approval or commercial launch. Its principal development code, DAR-010, was evaluated in early clinical studies for Parkinson's disease and schizophrenia-related symptoms. Public development activity appears inactive, and no current sponsor has established a late-stage program, regulatory filing, commercial manufacturing network, or launch timetable. Near-term revenue potential is therefore negligible. Long-term value depends on reformulation, new clinical evidence, and a new patent estate.
What is dihydrexidine and how does it work?
Dihydrexidine is a direct dopamine D1-family receptor agonist. Unlike levodopa, it does not require conversion to dopamine. Unlike dopamine D2 agonists such as pramipexole and ropinirole, it primarily stimulates D1/D5 receptors.
| Attribute | Dihydrexidine |
|---|---|
| Active ingredient | Dihydrexidine, generally studied as the hydrochloride salt |
| Development code | DAR-010 |
| Pharmacology | Selective D1/D5 dopamine receptor agonist |
| Primary research areas | Parkinson's disease; schizophrenia; cognition and motivational disorders |
| Regulatory status | Investigational; not FDA approved |
| Commercial status | No marketed product identified |
| Orange Book status | No FDA-approved listing identified |
| Biosimilar status | Not applicable |
| Primary development barrier | Limited clinical validation, delivery limitations, and uncertain intellectual-property protection |
D1 receptor signaling has been investigated for motor control, working memory, executive function, and reward processing. The clinical rationale is strongest in Parkinson's disease, where D1 stimulation could complement D2-based therapies and potentially improve motor function. The same pharmacology creates risks of dyskinesia, psychosis, agitation, cardiovascular effects, and dose-related tolerability problems.
What is the development status of dihydrexidine?
Dihydrexidine has reached human clinical testing but has not progressed to pivotal development. Publicly documented research has focused on small early-stage studies rather than a conventional Phase 2b or Phase 3 registration program.
Parkinson's disease development
Clinical studies evaluated dihydrexidine as a potential dopaminergic treatment for Parkinson's disease. The program examined motor effects, tolerability, and the feasibility of stimulating D1 receptors directly.
The main development constraints were:
- Short or otherwise difficult pharmacokinetic exposure.
- The need for nonstandard administration in some studies.
- Dose-limiting cardiovascular and central nervous system effects.
- Uncertainty about whether D1 activation would produce clinically meaningful benefit without worsening dyskinesia or psychosis.
- Lack of a commercially practical formulation with sustained exposure.
These issues limited the ability to position dihydrexidine against established oral therapies, including levodopa/carbidopa, dopamine agonists, MAO-B inhibitors, and newer levodopa delivery systems.
Schizophrenia and cognition development
Dihydrexidine was also investigated as a potential treatment for cognitive or negative symptoms associated with schizophrenia. D1 receptor stimulation has a nonlinear relationship with cognition: inadequate stimulation may impair performance, while excessive stimulation can also reduce performance or increase adverse effects.
The schizophrenia program did not establish a regulatory-grade efficacy profile. No approved indication, confirmatory trial, or active commercial development path has emerged from the available public record.
Development timeline
| Period | Development event | Commercial interpretation |
|---|---|---|
| 1980s-1990s | Preclinical D1 receptor agonist research and compound characterization | Established pharmacology but created an aging discovery asset |
| 1990s-2000s | Early human studies in Parkinson's disease and schizophrenia-related indications | Demonstrated clinical feasibility without establishing efficacy |
| 2000s-2010s | DAR-010-related clinical investigation | Development remained early stage |
| 2010s-2020s | Limited visible advancement toward registration | Program appears dormant or discontinued |
| 2024 public record | No FDA approval, NDA, commercial launch, or late-stage trial identified | No near-term product revenue base |
ClinicalTrials.gov records and the published literature document investigational activity, but they do not show a current registration program capable of supporting a launch. ClinicalTrials.gov; National Library of Medicine, n.d.; Sibley et al., 1994.
When could dihydrexidine reach the market?
No reliable launch date exists because dihydrexidine has not entered a visible registrational program.
If a sponsor restarted development, the minimum commercial path would likely include:
- A new formulation or delivery system.
- A contemporary Phase 1 pharmacokinetic and safety study.
- A focused proof-of-concept trial in one indication.
- Dose-ranging work against a clinically relevant comparator.
- Two adequate and well-controlled pivotal studies, unless the FDA accepted an alternative design.
- An NDA submission and review.
Under an aggressive restart scenario, approval would generally be several years away. A realistic timeline would be longer because the sponsor would need to recreate the clinical and manufacturing package rather than continue seamlessly from an active Phase 2 program.
The FDA has not granted dihydrexidine approval, breakthrough therapy designation, fast-track designation, or an approved orphan indication in the publicly identified record. FDA, 2024.
What patents protect dihydrexidine?
Dihydrexidine's patent position is a major commercial weakness. The compound was discovered and clinically studied decades ago, so any early composition-of-matter protection would likely have expired or be close to expiration in major markets.
No active FDA Orange Book patent listing has been identified because there is no approved dihydrexidine product. The absence of an Orange Book listing means there is no approved-product patent framework for automatic Paragraph IV litigation.
Potential protection could still be created around:
- New salts or crystalline forms.
- Stable solid-state compositions.
- Sustained-release oral formulations.
- Transdermal, subcutaneous, or depot delivery.
- Prodrugs with improved oral exposure.
- Combination therapy with levodopa or other Parkinson's medicines.
- Narrow method-of-use claims.
- Manufacturing processes that improve purity or yield.
These protections would not automatically restore broad exclusivity for the original molecule. Their value would depend on claim scope, clinical differentiation, patent term, obviousness risk, written-description support, and the ability of a generic manufacturer to design around the claims.
Patent strength assessment
| Patent layer | Likely position | Commercial strength |
|---|---|---|
| Original compound | Likely aged and vulnerable to expiration | Low |
| Original use claims | Potentially expired or narrow | Low |
| New formulation | Possible basis for exclusivity | Moderate if clinically necessary |
| Controlled-release delivery | Potentially valuable | Moderate |
| Prodrug | Stronger if pharmacokinetically differentiated | Moderate to high |
| Manufacturing process | Usually narrow and design-around risk is high | Low to moderate |
| Combination therapy | Dependent on clinical evidence and claim construction | Moderate |
A new sponsor would need to build a fresh patent estate rather than rely on the historical compound patent. No current Paragraph IV challenge, patent settlement, or US litigation involving an approved dihydrexidine product has been identified.
What is the FDA and Orange Book status of dihydrexidine?
Dihydrexidine is not an FDA-approved drug. It does not have an established USAN-to-NDA commercial history comparable to approved Parkinson's products.
| Regulatory question | Status |
|---|---|
| FDA approval | None identified |
| NDA or BLA | None identified |
| Orange Book listing | None identified |
| Approved indication | None |
| Reference listed drug | None |
| Generic approval pathway | Not available without an approved reference product |
| Biosimilar pathway | Not applicable because dihydrexidine is a small molecule |
| Hatch-Waxman Paragraph IV activity | None identified for an approved product |
Because the drug has no approved reference product, a future sponsor could not rely on a conventional abbreviated new drug application pathway for the active ingredient alone. A generic applicant would need an approved reference product or another legally available route. That does not eliminate competition risk, but it changes the regulatory sequence.
What clinical and manufacturing barriers affect development?
The most important technical issue is delivery. Direct D1 agonism requires sufficient receptor exposure without producing intolerable cardiovascular or psychiatric effects. A formulation that produces rapid peak concentrations may increase adverse events, while inadequate exposure may fail to produce motor or cognitive benefit.
A development program would likely require:
- Reproducible oral bioavailability.
- Controlled peak-to-trough exposure.
- Dose flexibility.
- Compatibility with levodopa and standard Parkinson's regimens.
- Long-term assessment of dyskinesia, hallucinations, impulse-control effects, and orthostatic hypotension.
- Scalable current good manufacturing practice production.
- Control of stereochemical purity, impurities, salt form, and solid-state characteristics.
Manufacturing itself is unlikely to create a durable barrier unless the sponsor patents a superior process or a difficult-to-reproduce formulation. The greater barrier is clinical translation: demonstrating that D1 activation adds benefit beyond levodopa and newer device-based or extended-release therapies.
How does dihydrexidine compare with competing Parkinson's drugs?
| Product or class | Primary mechanism | Regulatory position | Competitive advantage over dihydrexidine |
|---|---|---|---|
| Levodopa/carbidopa | Dopamine precursor | Established standard of care | Strong efficacy and broad physician familiarity |
| Pramipexole, ropinirole | D2/D3 agonism | Approved | Oral availability and commercial infrastructure |
| Apomorphine | Dopamine agonist | Approved in multiple delivery forms | Rescue and infusion options |
| Safinamide | MAO-B inhibition and glutamate modulation | Approved | Adjunct positioning with clinical evidence |
| Istradefylline | Adenosine A2A antagonism | Approved in the US | Non-dopaminergic adjunct option |
| Continuous levodopa delivery | Sustained dopaminergic therapy | Approved or advancing by product | Direct control of motor fluctuations |
| Dihydrexidine | D1/D5 agonism | Investigational | Mechanistic differentiation, but no demonstrated commercial advantage |
Dihydrexidine would need to show a clear benefit in one of three areas: reduction of motor fluctuations, improvement in dyskinesia without worsening psychosis, or treatment of a symptom domain poorly addressed by current therapy.
What market could dihydrexidine address?
The addressable market is large at the disease level but much smaller at the candidate level. Parkinson's disease affects millions of people globally, yet most patients would not automatically receive a D1 agonist. Initial use would likely be limited to patients with inadequate control on levodopa or those requiring adjunctive treatment.
A commercial forecast should distinguish between theoretical market size and realistic product revenue:
| Scenario | Development assumption | Commercial outcome |
|---|---|---|
| No restart | No sponsor or clinical program | Zero product revenue |
| Academic or orphan relaunch | Small indication and specialized formulation | Limited niche sales |
| Parkinson's adjunct approval | Demonstrated benefit in motor fluctuations | Potential specialty neurology product |
| Broad CNS success | Efficacy in Parkinson's plus cognition or negative symptoms | Large upside but low probability |
| Premium delivery system | Patented extended-release or implantable formulation | Higher price and stronger lifecycle protection |
A relaunch focused on Parkinson's disease would face established generic competition and payer pressure. A differentiated extended-release formulation could support specialty pricing, but only if it reduces off-time or dyskinesia and has a tolerability advantage.
The probability-adjusted commercial value is currently low because there is no visible late-stage program, no approved product, and no verified market exclusivity. A theoretical peak-sales range cannot be treated as a forecast without a defined sponsor, formulation, target indication, clinical efficacy, price, and launch geography.
Which companies are challenging or licensing dihydrexidine?
No active commercial licensing deal, acquisition, Paragraph IV challenger, or settlement agreement involving an approved dihydrexidine product has been identified in the public record.
Historical research involved academic and specialty drug-development organizations, but the asset has not produced the type of sustained corporate ownership seen with marketed Parkinson's therapies. Any new transaction would likely be structured around a reformulated product, a prodrug, or a new indication rather than the legacy molecule alone.
How strong is the overall commercial position?
Dihydrexidine has scientific interest but weak current commercial positioning.
| Factor | Assessment |
|---|---|
| Biological rationale | Moderate |
| Human proof of concept | Limited |
| Clinical differentiation | Unproven |
| Regulatory maturity | Low |
| Patent protection | Likely weak for the legacy molecule |
| Formulation opportunity | Potentially meaningful |
| Manufacturing complexity | Manageable but not a primary moat |
| Competitive intensity | High in Parkinson's disease |
| Near-term launch probability | Very low |
| Long-term upside | Dependent on new formulation and clinical validation |
Key takeaways
- Dihydrexidine is an investigational D1/D5 dopamine receptor agonist, principally associated with the DAR-010 program.
- It has undergone early clinical study in Parkinson's disease and schizophrenia-related research but has not reached approval.
- No FDA Orange Book listing, approved reference product, biosimilar pathway, or active Paragraph IV dispute has been identified.
- The original molecule's age creates a weak basis for new broad composition-of-matter exclusivity.
- Commercial value would depend on a new formulation, prodrug, delivery technology, or clinically differentiated method of use.
- No near-term launch or meaningful product revenue should be assumed.
- The most credible development strategy would focus on sustained exposure and a narrowly defined Parkinson's population with unmet motor-control needs.
FAQs about dihydrexidine development and market potential
Is dihydrexidine approved for Parkinson's disease?
No. Dihydrexidine has not received FDA approval or an approved Parkinson's disease indication.
Is DAR-010 the same drug as dihydrexidine?
DAR-010 is the development code associated with dihydrexidine, generally studied as the hydrochloride salt.
Can a generic company launch dihydrexidine?
Not through a standard ANDA based on an existing FDA reference listed drug, because no approved dihydrexidine reference product has been identified.
Does dihydrexidine have biosimilar competition?
No. Dihydrexidine is a small molecule, not a biologic. The relevant future competition would be generic or reformulated small-molecule products.
What would make dihydrexidine commercially viable?
A sponsor would need to demonstrate clinically meaningful benefit, create a practical sustained-exposure formulation, secure new patent protection, and establish an indication where current dopamine therapies provide inadequate control.
References
ClinicalTrials.gov. (n.d.). Search results for dihydrexidine and DAR-010. U.S. National Library of Medicine. https://clinicaltrials.gov/
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/ob/
National Library of Medicine. (n.d.). PubChem compound summary: Dihydrexidine. National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/
Sibley, D. R., Jewell-Motz, E. A., & others. (1994). Dopamine receptor pharmacology and the development of selective D1 receptor agonists. Journal of Pharmacology and Experimental Therapeutics.
National Institute of Neurological Disorders and Stroke. (n.d.). Parkinson's disease information. National Institutes of Health. https://www.ninds.nih.gov/health-information/disorders/parkinsons-disease
More… ↓
